Drug
Revumenib clinical trials
Also written SNDX-5613.
- studies test it
- 23
- open now
- 18
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the revumenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 8 |
| 2025 | 2 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 11
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 18
Syndax Pharmaceuticals (5) · M.D. Anderson Cancer Center (5) · SWOG Cancer Research Network (1) · UNC Lineberger Comprehensive Cancer Center (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Center for International Blood and Marrow Transplant Research (1) · St. Jude Children's Research Hospital (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Venetoclax (5) · Daunorubicin (4) · Azacitidine (3) · Cytarabine (3) · Gilteritinib (2) · Antineoplastic Agents (1) · Blinatumomab (1) · Mezigdomide (1)
Studies
Open first, then newest update. How each study uses revumenib is read from its arms, and is right about nine times in ten.
Testing it · 23
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as Revumenib
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationRecruitingPhase 3Syndax PharmaceuticalsNCT07211958Written as Revumenib
- A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07356154Written as Revumenib
- Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06575296Written as Revumenib
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Revumenib
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingPhase 1/2Syndax PharmaceuticalsNCT04065399Written as revumenib
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05360160Written as SNDX-5613
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06284486Written as Revumenib
- A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesRecruitingPhase 2M.D. Anderson Cancer CenterNCT06229912Written as Revumenib
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLNot yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07605949Written as Revumenib
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as SNDX-5613 (BAML-16-001-S17)
- Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLRecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT06652438Written as Revumenib
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingPhase 1National Cancer Institute (NCI)NCT05886049Written as Revumenib
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07283640Written as Revumenib
- Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."Not yet recruitingPhase 2Therapeutic Advances in Childhood Leukemia ConsortiumNCT07686107Written as Revumenib
- Menin-Inhibitor Targeted Maintenance in AMLNot yet recruitingPhase 2Center for International Blood and Marrow Transplant ResearchNCT07563010Written as Revumenib
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationRecruitingPhase 1Uma BorateNCT06222580Written as Revumenib
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingPhase 1Richard Stone, MDNCT06313437Written as Revumenib
- A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia PatientsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT07052994Written as Revumenib
- A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasActive, not recruitingPhase 1Syndax PharmaceuticalsNCT06226571Written as Revumenib
See all 23 studies that test revumenib →
Given in every arm · 3 — revumenib is usual care beside what is tested
- Revumenib in Patients With MyelofibrosisNot yet recruitingPhase 1/2John MascarenhasNCT07734077Written as Revumenib
- A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT05761171Written as Revumenib
- A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute LeukemiaCompletedPhase 1Syndax PharmaceuticalsNCT05326516Written as Revumenib
Codes
What other systems call revumenib · ClinicalTrials.gg INT002034
- MeSH (NLM) C000728983revumenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LZ0M43NNF2REVUMENIBConfirmed FDA, NLM
- NCI Thesaurus C165776RevumenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000728983 | revumenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LZ0M43NNF2 | REVUMENIB | Confirmed FDA, NLM |
| NCI Thesaurus | C165776 | Revumenib | One source FDA |
Also registered as revumenib citrate (UNII YL4RYN734D) and revumenib sesquifumarate (UNII 75HI05N8HS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.